Considering that SELENOW is highly expressed in multiple myeloma and that it promotes osteoclast differentiation, we analyzed the molecular mechanisms underlying SELENOW upregulation in multiple myeloma with an increase in circulating osteoclastogenic factors, including M-CSF, RANKL, IL1β, and TNFα. This evidence concerns the gene IL1B and plasma cell myeloma.